Revenio Group Corporation: Financial reporting and annual general meeting in 2017
Revenio Group Corporation, Stock Exchange Release, December 19, 2016 at 11.00
REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2017
During 2017, Revenio Group Corporation will publish the following financial reports:
- Financial Statements bulletin in regard to 2016 on Thursday, February 16, 2017
- Interim Report 1-3/2017 on Thursday, April 20, 2017
- Interim Report 1-6/2017 on Monday, August 7, 2017
- Interim Report 1-9/2017 on Thursday, October 26, 2017
Due to an amendment in the Securities Market Act, which came into force on 26 November 2015, Revenio will publish the descriptive sections of its interim reports for 1-3/2017 and 1-9/2017 in a more concise form than before. The table sections will be reported in accordance with previous practices.
The Annual General Meeting is planned to be hold on Wednesday, March 22, 2017. The Board of Directors will give a separate notice of the Annual General Meeting later.
A shareholder, who wishes to place an item on the agenda of the Annual General Meeting, shall submit the request in writing to the company's Board of Directors by February 3, 2017. Such requests including the reasoning or a resolution proposal can be submitted to the address: Revenio Group Corporation / Board of Directors, Äyritie 22, FI-01510 Vantaa, Finland.
The Annual Report for 2016 will be published on Group's website www.revenio.fi during week 9 in 2017.
Revenio Group Oyj
Olli-Pekka Salovaara
CEO
For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi
DISTRIBUTION:
NASDAQ Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.